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Abstract 
The discovery of bioactive small molecules is generally driven via iterative design-make-purify-
test cycles.  Automation is routinely harnessed at individual stages in order to increase the 
productivity of drug discovery.  We describe recent progress to automate and integrate two or 
more adjacent stages within discovery workflows. The value of these integrated technologies 
is illustrated in the context of specific discovery case studies.  We note that, to maximise 
impact on the productivity of discovery, each of the integrated stages would need to have both 
high and matched throughput.  We also consider the longer-term goal of realising the fully 
autonomous discovery of bioactive small molecules through integration and automation of all 
stages of discovery.  
 
1. Introduction and Vision 
The grand challenge of increasing productivity within the pharmaceutical sector1 has led 
to the automation of many parts of the drug discovery process.2  For example, high-throughput 
screening of large compound collections is widely exploited to generate series of hit 
molecules.3  In addition, arrays of molecules are often synthesised and purified using 
automated approaches4 significantly reducing the volume of labour-intensive tasks required.  
Currently, however, automation within discovery workflows almost always focuses on isolated 
individual stages of the discovery process (Figure 1). 
The quest to improve the productivity of drug discovery, however, is at odds with the 
aspiration to increase chemical and biological innovation.  The targets of the future, such as 
protein-protein interactions and large macromolecular complexes, are likely to bring new 
scientific challenges and to require different classes of ligand.5  The challenge of discovering 
such ligands is, however, heightened by the vastness of chemical space: although estimates 
vary extremely widely, extrapolation from GDB-17 (a database of enumerated molecules with 
up to 17 heavy atoms) led to an estimation of §1033 possible molecules with up to 36 heavy 
atoms.6  Yet FKHPLVWV¶ KLVWRULFDO H[SORUDWLRQ RI FKHPLFDO VSDFH KDV DOUHDG\ EHHQ KLJKO\
uneven and unsystematic,7 and this lack of scaffold diversity is also reflected in exemplified 
medicinal chemistry space8 and drugs.9  Furthermore, despite overwhelming recognition of 
the importance of molecular properties in drug discovery,10,11 medicinal chemists are actually 
increasing their attention on more lipophilic and flat compounds 12,13  This behaviour is driven, 
in large part, by current discovery workflows that are underpinned by a remarkably narrow 
(though gradually increasing13) toolkit of robust reaction types.14-17  The introduction of new 
ultra-high throughput chemical technologies, such as DNA-encoded libraries,18 can greatly 
increase the number of compounds explored, albeit generally with a more limited palette of 
underpinning reaction classes.  How then can the productivity of drug discovery be improved, 
whilst enabling currently challenging targets to be addressed? 
 
Figure 1 | Current features and future aspirations in drug discovery workflows 
 
In this Perspective, we describe progress towards the automation and integration of 
adjacent stages within discovery workflows.  We have deliberately focused on integrated 
approaches that have already been exploited in discovery, rather than on isolated methods 
that have future potential to be integrated into discovery workflows.  To provide context, the 
value of the integrated approaches is illustrated using specific case studies.       
 
2. Integrated Platforms to Drive Bioactive Small Molecule Discovery 
The automation of chemical synthesis4,19 can significantly increase the efficiency and 
reproducibility of synthetic chemistry within discovery workflows.  Although the adoption of 
parallel synthesis is widespread, compound purification is almost always performed in series.  
This bottleneck is imposed by the technologies that are widely adopted (such as mass-
directed HPLC), and the limited scope of current parallel purification approaches (which 
include scavenging20 and extraction21).  Many reaction classes have been automated, 
including multi-phase reactions; and the automation of the dominant reactions within the 
medicinal chemistry toolkit ± such as heteroatom functionalisations and metal-catalysed 
cross-couplings ± is widespread.  Furthermore, automated multi-step synthesis is possible, 
for example, in the synthesis E- and J-amino acid derivatives using several different reaction 
classes.22   Although the broader context of automated synthesis is relevant to this 
Perspective, we focus here on approaches in which the automation of synthesis has been 
integrated with adjacent stages within discovery workflows. 
 
2.1 Integration of Reaction Optimisation and Synthesis 
The molecules that are designed within medicinal chemistry programmes generally need 
to be prepared from polar and functionalised substrates.11,23  Such reactants tend to perform 
systematically poorly in chemical reactions, resulting in a significant drift in logP between 
designed and produced arrays.23  Several teams24-28 have therefore developed high-
throughput approaches for the optimisation of reactions within medicinal chemistry workflows.   
The ability to explore many different reaction parameters29 rapidly, using small amounts of 
material, can significantly increase the value of specific reaction classes in discovery 
applications.  Although published examples are essentially limited to the standard medicinal 
chemistry toolkit (Table 1), these approaches should ultimately broaden the range of 
underpinning reactions that can be reliably harnessed for molecular discovery.  For example, 
C-H functionalisations at sp3-hybridised carbon offer great promise17 for, but are largely 
untapped in, drug discovery.30, 31  Notably, high-throughput experimentation can also enable 
the initial discovery of new catalytic reactions32 and the identification of transformations that 
are particularly functional group-tolerant.33 
 
Table 1. Case studies based on platforms that can integrate reaction optimisation with small 
molecule synthesis 
Reaction Type Format Optimisation demonstrated? Quantification/Purification Ref. 
Suzuki-Miyaura Oscillator Flow (series) Partial HPLC purification 24 
Suzuki-Miyaura Flow (series) Yes HPLC purification 25 
SNAr Batch (vials) (parallel) Yes HPLC, UV & MS analysis 26 
CC, CO and CN Pd-
catalysed couplings Batch (plates) (parallel) Yes 
LC-MS (For product 
detection) 27 
CC, CO and CN Pd-
catalysed couplings Flow (series) Yes 
LC-MS (For product 
detection) 28 
HPLC, high-performance liquid chromatography; UV, ultraviolet; MS, mass spectrometry; LC-MS, liquid 
chromatography-mass spectrometry. 
 
The high-throughput optimisation of palladium-catalysed cross-couplings leading to highly 
functionalised products has been conducted on a nanomole scale (Figure 2, Panel A).27  
Metal-catalysed couplings, including Suzuki-Miyaura and Buchwald-Hartwig reactions, have 
received particular attention since significant optimisation is often needed for each pair of 
substrates.  The study focused on palladium-catalysed CC, CO and CN bond-forming 
reactions involving combinations of 12 polar nucleophiles and 8 complex electrophiles.  Initial 
attempts to synthesise the 96 possible products in 96-well format on a 500 Pmol scale had 
resulted in 54 successful reactions (Panel A1). 
For the optimisation study, arrays of reactions were set up in plastic 1536-well plates 
using a nanolitre liquid-handling robot.  The reactions were performed on a ~100 nmol scale 
in 1.0 PL DMSO at room temperature without agitation, and the outcomes were determined 
using mass spectrometry.  Attention was focussed on 32 nucleophile/electrophile 
combinations that had failed during the initial synthesis (see above).  These 32 combinations 
were each subjected to 48 different conditions (6 catalysts x 8 organic superbases), leading 
to a total of 1536 test reactions.  For 21 of the combinations, the required product mass was 
detected, and 16 of the products were successfully isolated after subsequent scale up (to 500 
Pmol). For six of the remaining failed reactions, 48 combinations of reagent stoichiometry and 
catalyst loading were then explored, and better conditions were identified in five cases.  Thus, 
from these two high-throughput experiments, 21 complex products that had previously eluded 
synthesis could be prepared (see Panel A2 for an example).  Finally, to demonstrate that 
nanomole reaction optimisation can inform the development of practical gram-scale 
syntheses, it was shown that conditions identified on a 0.02 mg scale did enable efficient 
coupling of the chloride 4 and the amine 5 on 25 mg and 1 g scales (Panel A3). 
 Figure 2 | Platforms for high-throughput reaction optimisation to yield highly-functionalised products. (A) Batch-
based nanomole-scale optimisation.  A1: Overview of platform. A2: Identification of conditions for the reaction of 
electrophile 1 and nucleophile 2 to give the product 3. A3: Successful reaction of the electrophile 4 and the 
nucleophile 5 on 0.02 mg, 25 mg and 1.0 g scales to generate the product 6. (B) Flow-based nanomole-scale 
reaction optimisation. B1: Overview of platform.  B2: Range of substrates, ligands and bases explored in the 
optimisation of a Suzuki-Miyaura coupling, and translation of the optimised reaction to conventional batch- and 
flow-based approaches. DAD, diode array detector; MSD, mass-selective detector.  
In another reaction optimization study, an automated flow-based platform was harnessed 
that enables both nanomole-scale reaction screening and micromole-scale synthesis (Figure 
2, Panel B).28  As an exemplar, a SuzukiMiyaura coupling was optimised through exploration 
of 5760 combinations of 15 pairs of substrates, 12 ligands, 8 bases and 4 solvents. Although 
the approach is inherently serial in nature, high-throughput operation (>1500 per day) was 
possible. The 5760 reaction conditions were explored by injection of the appropriate 
components into the same flow segment, and analysis of reaction outcome by LC-MS (Panel 
B1).  Furthermore, it was demonstrated that the required product could be prepared on a 
micromole scale on the platform through repetition of the optimised reaction; and on 50-200 
mg scale in standard flow and batch modes (Panel B2). 
The integration of high-throughput reaction optimisation into discovery workflows is 
particularly valuable when bespoke conditions are required for each specific combination of 
reactants.  High throughput is possible either by operation in parallel (in batch mode) or in 
series (e.g. in flow mode with a fast cycle time).  To achieve full impact, it will be necessary to 
exploit these platforms to harness a wider range of underpinning reaction classes within 
discovery workflows. 
 
2.2 Integration of Synthesis and Biological Evaluation 
Several platforms that integrate automated synthesis and biological evaluation have been 
developed and exemplified in bioactive molecule discovery (Table 2).34-42  These platforms 
generally have chemical reactor module(s), off-line compound processing unit(s) and a 
biological testing module.  Inherently modular systems can enable flexible configuration to 
meet the needs of specific discovery projects. 
Throughput depends on both the timescale of, and the parallel or serial nature of, the 
activities that are performed.  For example, in a programme focused on the polycomb protein 
EED,36 batch synthesis in vials (in parallel), mass-directed HPLC purification (in series), and 
a plate-based biochemical assay (in parallel) enabled the synthesis and evaluation of 22 
compounds in ~24 hr.  The throughput of a programme focused on the peptidase DPP4 was 
similar (~2 hr / compound), and was driven by synthesis in a microfluidic reactor (in series), 
HPLC purification (in series) and a plate-based biochemical assay (in parallel).37 
In-line continuous flow technologies can enable multiple stages within drug discovery 
workflows to be integrated.  For example, affinity chromatography has been exploited to 
determine immediately the affinity of synthesised compounds for a target protein.38,39  The 
approach is particularly valuable when in-line purification is possible, as has been 
demonstrated in the discovery of ligands for human serum albumin.39  Here, it was also 
demonstrated that manual operations could be omitted through dilution of reaction products, 
and direct injection onto the affinity column.39 
Integrated flow technologies have been exploited in the discovery of inhibitors of the 
protease BACE1 (Figure 3, Panel A).40  The on-chip assay technology integrated a thin 
capillary (to generate a ligand concentration gradient over several orders of magnitude) and 
a glass chip that enabled activity assessment in flow after combining ligand, enzyme and 
substrate streams.  Measurement of fluorescence at different locations on the chip enabled 
dose-dependent activity determination at 100 different ligand concentrations.  The use of flow 
technologies at all stages enabled each compound to be prepared, purified and evaluated in 
series in ~1 hr.  The approach enabled the SAR of a series of inhibitors (e.g. 7 and 8) to be 
defined. 
A platform that integrated reaction optimisation, library synthesis and biological evaluation 
was exploited in the discovery of CHK1 kinase inhibitors (Figure 3, Panel B).41  An array of 
384 target compounds was designed that would be accessible via coupling of the 2-
bromothiazole 9 with 384 different nucleophiles: 48 thiols (for CS cross-couplings); 32 
alkynes and 80 boronates (for CC cross-couplings); 64 alcohols (for CO cross-couplings); 
and 32 amides, 32 sulfonamides and 96 amines (for CN cross-couplings).  Initially, four 
productive reaction conditions were identified for each class of nucleophile.  The 384 cross-
couplings were then each performed on a ~100 nmol scale under the four reaction conditions.  
By exploiting the best of the four alternative conditions, 345 of the 384 targeted products could 
be prepared (compared with just 158 products using a single reaction condition).  Pools of 12-
24 reaction products were then incubated with the target protein and eluted through a size-
exclusion column to remove unbound compounds, and the identity of the bound compounds 
was determined by mass spectrometry.  By varying the concentration of the target protein, it 
was possible to rank ligands by affinity for the target protein.  The activity of a range of 
compounds (e.g. 10a-10c) was confirmed after re-synthesis on a 50 Pmol scale. 
 
  
Table 2: Case studies that exploit technology platforms that integrate small molecule 
synthesis and biological evaluation. 
Synthesis Purification Biological Evaluation 
Target Ref. 
Reaction Format Format Assay type Format 
SN2, transesterification, 
and sulfonamide 
formation 
Microfluidic chip 
(series) None
a
 Biochemical Caliper-chip (series) 
T cell tyrosine 
phosphatase 34 
Click chemistryb Microfluidic chip (parallel) 
Solid phase extraction 
(parallel) b 
Bovine carbonic 
anhydrase II 35 
Acylation, 
Buchwald, and amination 
Vial-based 
(parallel) 
HPLC-MS  
(series) Biochemical 
Plate-based 
(parallel) 
Polycomb Protein 
EED 36 
SN1 and 
Boc-deprotection 
Flow/Microfluidic 
(series) 
LC-MS  
(series) Biochemical 
Plate-based 
(parallel) DPP4 37 
Curtius rearrangement Flow-based
c
 
(series) 
Prep-HPLC  
(series) FAC-MS
d,e
 
Flow-based 
(series) 
 BRD9 
bromodomain 38 
Condensation,  
5-exo cyclisation,  
amidation, and 
saponification 
Flow-based 
(series) 
In-line scavenging and 
silica plugf (series)  FAC-MS
d
 
Flow-based 
(series) 
Human serum 
albumin 39 
N-acylation Flow-based (series) 
Prep-HPLC and LC-MS 
(series) Functional 
On-chip 
(series) BACE1 40 
C-O, C-N, C-C and C-S 
cross-couplings 
Plate-based 
(parallel) None 
Affinity-selection 
mass spectrometry 
Pools of products 
(series) CHK1 kinase 41 
Sonogashira coupling Flow/Microfluidic (series) 
Silica cartridge and  
LC-MS (series) Biochemical 
Plate-based 
(parallel) ABL1 kinase 42 
aThe eluted product stream was split into two for LC-UV-MS analysis and direct screening. bIn situ click chemistry 
catalysed by the target protein was analysed by MS. cReaction precursors were prepared using batch synthesis. 
dFrontal Affinity Chromatography was used to evaluate ligand binding to immobilised protein. eThe immobilised 
protein was stable up to 6 months. fSolvent removal and manual preparation were carried out prior to screening. 
Direct injection of product aliquot into the FAC assay was also possible after appropriate dilution. HPLC, high-
performance liquid chromatography; UV, ultra violet; MS, mass spectrometry; LC-MS, liquid chromatography-mass 
spectrometry; FAC-MS, frontal affinity chromatography-mass spectrometry; DPP4, dipeptidyl peptidase-4; BACE1, 
Beta-secretase 1. 
 
 Figure 3 | Platforms that integrate synthesis and biological evaluation to enable bioactive small molecule discovery. 
(A) Application of an integrated platform in the discovery of BACE1 inhibitors. A1: Schematic illustration of the 
integrated workflow. A2: Exemplar ligands that were synthesised and tested against BACE1; the on-chip biological 
evaluation was validated using a plate-based assay. (B) Integration of nanoscale synthesis and affinity ranking in 
the discovery of CHK1 inhibitors.  B1: Schematic illustration of the integrated workflow.  B2: Exemplar CHK1 
inhibitors that were discovered. 
 
The efficiency of the experimental exploration of predefined regions within chemical space 
can be increased using active learning models.43  Such models are initially built from training 
data, and are continuously refined in real time in the light of the activity of the new compounds 
that are synthesised.  In a programme focussed on ABI1 kinase inhibitor discovery42 (Figure 
4 and Table 2), active learning was used to drive molecular discovery through integration with 
microfluidic-based synthesis, purification and biochemical evaluation.  A model was initially 
constructed on the basis of the biological activity of 32 known inhibitors. Using Ponatinib as a 
template, potential Asp-Phe-Gly (DFG) binding motifs and hinge-binding heterocycles were 
combined to define a virtual library. Ten aryl iodides (with a potential DFG-binding motif) and 
27 alkynes (with a potential hinge-binding motif) were prepared, giving a total of 270 potential 
Sonogashira coupling products.  To establish SAR quickly, and to accelerate the refinement 
of the model, 29 diverse products were targeted in the first round (Mode A, see Figure 4), of 
which 22 were successfully prepared and evaluated.  The aim of the second round was to 
optimise potency within the previously identified hotspots (Mode B, see Figure 4): 20 
compounds were targeted of which 14 were successfully investigated.  In the final round, a 
combination of the two strategies was used.  Overall, in a total of 90 cycles, 64 new 
compounds (of the 270 possibilities) were synthesised and evaluated with a successful 
completion rate of 71%.  The self-refining active learning model avoided the need for 
exhaustive SAR studies, and 31 novel inhibitors with IC50 < 50 nM (e.g. 11 and 12) were 
identified in a total of 135 hr machine time. 
Although several platforms have been developed that integrate small molecule synthesis 
and biological evaluation, throughput is rarely matched at all stages, and some manual 
operations (e.g. purification, characterisation, quantification and solvent reformatting) are 
often required.  In particular, compound purification is usually performed in series, even when 
synthesis and biological evaluation are possible in parallel, and can interrupt otherwise 
integrated workflows.  Thus, approaches that enable parallel compound purification, or the 
preliminary assessment of binding using partially-purified reaction products,44 may have 
particular value in integrated discovery workflows.   
 
 Figure 4 | Integration of active learning, synthesis, purification and evaluation in the discovery of ABI kinase 
inhibitors. (A) Schematic illustration of the integrated workflow with (i) machine-guided design to identify activity 
hotspots (Mode A) or optimise activity (Mode B), (ii) flow-based synthesis, (iii) compound purification and 
reformatting, and (iv) biological evaluation using a plate-based assay. (B) A initial heat map of predicted ABl1 
activities was continuously refined through 90 design-synthesis-test loops. 
  
2.3 Function-Directed Molecular Discovery 
Current discovery workflows focus on the design of specific molecules that are then 
deliberately prepared and evaluated.  The narrow toolkit of robust reactions that may be 
accommodated within such workflows can inadvertently limit the diversity of chemical space 
that may be explored.  In stark contrast, the emergence of natural products is structure-
blind,45,46 and is driven by functional benefit to the host organism.  Notably, the diverse 
functions of natural products have inspired the discovery around a third of FDA-approved 
drugs.47 
Activity-directed synthesis (ADS) is a function-directed approach that borrows some 
concepts from the emergence of biosynthetic pathways that yield natural products.48,49 A 
conceptually-similar approach ± synthetic fermentation ± has also been developed, and has 
been exemplified in the discovery of E-peptide-based inhibitors of hepatitis C virus (HCV) 
NS3/4A protease.50  ADS and synthetic fermentation are complementary to dynamic 
combinatorial chemistry in which the most potent ligands are favoured via synthesis under 
thermodynamic control in the presence of a target protein.51 
In ADS, inherently promiscuous reactions ± with many possible outcomes ± are 
deliberately harnessed to facilitate the discovery of unexpected bioactive chemotypes.  
Initially, a reaction array is designed in which the components (substrates, catalysts, solvents) 
used in reactions are widely varied.  After catalyst scavenging, the crude reaction products 
are evaporated, dissolved in DMSO, and evaluated for biological function.  The design of 
reaction arrays in subsequent rounds is informed by reactions that are known to yield bioactive 
products.  The identity of the responsible bioactive ligands is only revealed after scale-up of 
the promising reactions, purification and functional validation. 
ADS has been exploited in the discovery of agonists of the androgen receptor (AR) 
(Figure 5).  Here, metal-catalysed carbenoid chemistry has been exploited in both intra-48 and 
an intermolecular49 senses.  For the intramolecular reactions, twelve substrates were 
designed that contained a diazo group; the 4-cyano-3-trifluoromethyl phenyl fragment known 
to target AR; and a potentially reactive side chain.  It was shown retrospectively that ADS can 
drive both optimisation of ligand structure and the corresponding synthetic route.  For 
example, a bioactive E-lactam 14 was produced from 13 in round 1, and its yield was optimised 
in round 2 through exploitation of a wider range of catalysts and solvents.  Finally, introduction 
of a related substrate 15 in round 3 enabled the identification of a related E-lactam 16.  Over 
the three rounds, a total of 336 reactions was performed, but only three ligands needed to be 
purified and structurally elucidated.  Crucially, the chemotypes discovered had no annotated 
AR activity, and the most potent ligands identified had sub-micromolar activity.  It was 
subsequently demonstrated that harnessing intermolecular reactions can expand the 
chemical space explored, and facilitate the discovery of further novel and unexpected 
bioactive chemotypes (e.g. 18 and 19).49 
 
Figure 5 | Activity-directed synthesis of androgen receptor agonists. (A) Reaction array design. (B) Activity-directed 
synthesis workflow.  (C) Evolution of intramolecular reactions that yield bioactive small molecules. (D) Scale-up of 
prioritised reactions, and product isolation, structural elucidation and biological evaluation; exemplar bioactive 18 
and 20 are shown. 
 
Function-directed approaches have the potential to drive the discovery of bioactive small 
molecules.  Such approaches do not require structural information, and can deliberately 
harness promiscuous reactions to enable diverse regions within chemical space to be 
explored.  All parts of the discovery workflow can be performed in parallel: the design and 
implementation of reaction arrays, and the scavenging and evaluation of the reaction products.  
Crucially, resources are then only focused on scaling up and evaluating the products of 
prioritised reactions that yield active products.  Although function-directed approaches have 
only been exemplified against a limited range of targets, it has been shown than unexpected 
chemotypes can emerge, in parallel with an associated synthetic route. 
 
 
 
3. Conclusions and Outlook 
Significant progress has been made towards realising the fully integrated discovery of 
bioactive small molecules.  It has been shown that adjacent stages within design-make-purify-
test-analyse cycles can be integrated, and can facilitate the discovery of novel functional 
molecules.  Crucially, the integration of reaction optimisation into discovery workflows has 
potential to expand significantly the chemical space that may be explored.  Specifically, the 
ability to optimise the synthesis of each target molecule should encourage the adoption of a 
wider reaction toolkit (for example, CH functionalisations) within discovery programmes.  To 
maximise the impact on the productivity of discovery, the throughput of the stages within 
workflows should be both high and matched.  To avoid the interruption of otherwise integrated 
workflows, technologies for parallel purification, and that enable assessment of the activity of 
partially-purified reaction products, may have particular value.  In addition, we note that 
integration of a wider range of measurements on synthetic products ± for example, to capture 
selectivity and physicochemical properties as well as affinity for the target protein ± would 
have significant value in informing subsequent molecular design. 
There are isolated examples of discovery programmes in which reaction optimisation, 
synthesis and biological evaluation have been fully integrated.  Perhaps unsurprisingly, these 
underpinning technology platforms vary significantly.  The discovery of CHK1 kinase inhibitors 
integrated reaction optimisation (via HPLC-MS) and the assessment of the binding of 
unpurified reaction products (using affinity-selection mass spectrometry) (Figure 3, Panel B).41  
Although relatively standard coupling chemistry was exploited, the underpinning technology 
platform may nonetheless enable a wider reaction toolkit to be exploited in discovery.  The 
activity-directed synthesis of androgen receptor agonists exploited metal-catalysed reactions 
that had many possible outcomes (Figure 5).49,50  Here, biological evaluation of the crude 
reaction products enabled both the ligand structure and the corresponding synthetic route to 
be optimised in parallel. 
The realisation of autonomous bioactive molecular discovery would require integration of 
technologies to drive all stages within iterative cycles of molecular design, synthesis and 
evaluation.  In addition to the experimental platforms described in this Perspective, integration 
of computational approaches would be required to enable the design of follow-up compounds 
(and their corresponding syntheses).  Computation tools are now available to support the 
prediction of the outcome of chemical reactions,52,53 and the design of follow-up molecules 
with desirable properties (including affinity, selectivity and physicochemical profiles).2,43,54,55 
However, the integration of all of these components remains an unmet challenge that is 
nonetheless needed to realise fully autonomous molecular discovery! 
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